Скачать или смотреть Next-Gen Targets and Therapies: From PARPs to Radioligands and ADCs

A regional roundtable discussion, moderated by Ulka Vaishampayan, MD, University of Michigan, offers a grounded, practical view of how academic oncologists are personalizing therapy across the prostate cancer continuum, from frontline treatment and ARPI selection to triplet therapy, biomarker integration, and emerging targeted agents like PARP inhibitors and radioligand therapy. Dr. Vaishampayan was joined by Robert Dess, MD, University of Michigan; Frank Cackowski, MD, PhD, Karmanos Cancer Institute; and three other individuals from University of Michigan: Phillip Palmbos, MD, PhD; Todd Morgan, MD; and Phoebe Tsao, MD.

In the final segment, the expert panel concludes with the evolving role and challenges of PARP inhibitors in prostate cancer treatment, the complexities of sequencing therapies, emerging novel targets like EZH-2 and B7H3ADC, and the need for personalized approaches in managing diverse patient populations.